Specify a stock or a cryptocurrency in the search bar to get a summary
Biomea Fusion Inc
BMEABiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California. Address: 900 Middlefield Road, Redwood City, CA, United States, 94063
Analytics
WallStreet Target Price
46.88 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BMEA
Dividend Analytics BMEA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BMEA
Stock Valuation BMEA
Financials BMEA
Results | 2019 | Dynamics |